[HTML][HTML] Cisplatin for cancer therapy and overcoming chemoresistance
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
[PDF][PDF] Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, M Mathai, A Zulli - core.ac.uk
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
[HTML][HTML] Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - ncbi.nlm.nih.gov
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, M Mathai, A Zulli - Heliyon, 2022 - vuir.vu.edu.au
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
Cisplatin for cancer therapy and overcoming chemoresistance.
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - europepmc.org
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - pubmed.ncbi.nlm.nih.gov
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - ui.adsabs.harvard.edu
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
[HTML][HTML] Cisplatin for cancer therapy and overcoming chemoresistance
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - Elsevier
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
Cisplatin for cancer therapy and overcoming chemoresistance.
R Ranasinghe, ML Mathai, A Zulli - Heliyon, 2022 - europepmc.org
Cisplatin spearheads the anticancer chemotherapeutics in present-day use although acute
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …
toxicity is its primary impediment factor. Among a plethora of experimental medications, a …